So Thian Chew have a 15 minute presentation to 180 Markets...

So Thian Chew have a 15 minute presentation to 180 Markets clients:

Thian is ex Goldman Sachs and appears to be a very polished operator with a deep understanding of investment across the full risk spectrum.

- Firstly, he wasn’t surprised by the immune response for the TNBC PoC. In previous PoC where they treated mice with ovarian cancer, they observed the tumour get smaller and smaller without the light being shined on it.
- next steps on the TNBC will be to obtain more data on the immune response and conduct testing on metastatic models
- when deciding on which indications to go to clinical trial, shorter timeframe trials (structured to get early interim data) and accelerated approval pathways are the priority. Speed to outcomes seems to be the important KPI rather than the market size of the indication
- on the AID - much earlier in the journey vs cancer. Next 6-12m is to identify a small number of target indications
- the territory expansion for cancer ($5m licence payment) covers all APAC ex China, Korea and Japan. IVX would need to fund the pre-clinical and clinical trials in those new territories, but the idea is a plug and play approach to piggyback off the RMW funded work in ANZ so basically get more bang for buck
- Apaarently Michael Cho is IVX R&D manager and is “fully focused” on Photosoft. Thian described the PDT as Cho’s “number 1 priority and objective in life”

The most important ‘reveal’ to me was when asked a pretty ordinary question about getting FDA approval, his response was the US market was “not who we are AT THE MOMENT”…in other words, i think the strategy will be to roll out the treatment into bigger markets if it proves successful, as an expansion to the plug and play Thian described in terms of the new territories for cancer.